Most cited papers from Alexandra Hospital

Alexandra Hospital

What are the most cited papers from Alexandra Hospital?

The most cited paper from Alexandra Hospital is "Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015" (Christina Fitzmaurice et al., 2016), with 6,333 citations. Next come "Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer" (2,702) and "International uniform response criteria for multiple myeloma" (2,662).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 232 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 Christina Fitzmaurice et al. · JAMA Oncology Open access185 authors	5 Dec 2016	6,333
2	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi et al. · New England Journal of Medicine Open access	5 Jun 2022	2,702
3	International uniform response criteria for multiple myeloma Brian G.M. Durie et al. · Leukemia	20 Jul 2006	2,662
4	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Thomas B. Powles et al. · The Lancet Open access	18 Dec 2017	1,437
5	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up Nicoletta Colombo et al. · Annals of Oncology Open access	4 Dec 2015	1,411
6	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma A. Keith Stewart et al. · New England Journal of Medicine Open access	6 Dec 2014	1,342
7	Anthropometric, Hemodynamic, Metabolic, and Renal Responses during 5 Days of Food and Water Deprivation Ioannis A. Papagiannopoulos, Vassilis I. Sideris, Michael Boschmann et al. · Complementary Medicine Research Open access	2013	1,129
8	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 Christopher J L Murray et al. · The Lancet Open access366 authors	21 Jul 2014	998
9	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders Angela Dispenzieri et al. · Leukemia Open access	20 Nov 2008	817
10	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 Haidong Wang et al. · The Lancet Open access230 authors	2 May 2014	814
11	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Jesús F. San Miguel et al. · The Lancet Oncology Open access	2 Sep 2013	804
12	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Helena Linardou, Issa J Dahabreh, Dimitra Kanaloupiti et al. · The Lancet Oncology Review	18 Sep 2008	747
13	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group Nelson Leung et al. · Nature Reviews Nephrology ReviewOpen access	3 Dec 2018	553
14	Organ-specific manifestations of COVID-19 infection Maria Gavriatopoulou, Eleni Korompoki, Despina Fotiou et al. · Clinical and Experimental Medicine Open access	27 Jul 2020	521
15	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Thomas Powles et al. · The Lancet Oncology Open access227 authors	21 Sep 2020	509
16	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma Meletios Athanasios Dimopoulos, Evangelos Terpos, Raymond L. Comenzo et al. · Leukemia	7 May 2009	482
17	Domestic Violence During the COVID-19 Pandemic: A Systematic Review Anastasia Kourti, Androniki Stavridou, Eleni D. Panagouli et al. · Trauma Violence & Abuse ReviewOpen access	17 Aug 2021	474
18	Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls George P. Nassis, Katerina Papantakou, Katerina Panagiotis Skenderi et al. · Metabolism	27 Oct 2005	471
19	Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study Noopur S Raje, Evangelos Terpos, Wolfgang Willenbacher et al. · The Lancet Oncology	9 Feb 2018	450
20	The Pap test: George N. Papanicolaou (1883–1962) S. Michalas · European Journal of Obstetrics & Gynecology and Reproductive Biology	Jun 2000	428
21	Diagnosis of monoclonal gammopathy of renal significance Frank Bridoux, Nelson Leung, Colin A. Hutchison et al. · Kidney International	21 Jan 2015	425
22	Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review Emmanuel N. Kontomanolis, Antonios Koutras, Athanasios J. Syllaios et al. · Anticancer Research Open access	27 Oct 2020	407
23	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial Meletios Athanasios Dimopoulos, Hartmut Goldschmidt, Rubén Niesvizky et al. · The Lancet Oncology	23 Aug 2017	406
24	Etiology of Anemia in Patients With Advanced Heart Failure John N. Nanas, Charis Matsouka, Drosos E. Karageorgopoulos et al. · Journal of the American College of Cardiology Open access	29 Nov 2006	404
25	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 Spyridon G. Deftereos et al. · JAMA Network Open Open access	24 Jun 2020	403
26	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 Silke Gillessen et al. · European Urology Open access	27 Jan 2020	400
27	Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial Domenica Lorusso et al. · The Lancet	20 Mar 2024	398
28	U‐shaped relationship between mortality and admission blood pressure in patients with acute stroke K. N. Vemmos, Georgios K. Tsivgoulis, Konstantinos M. Spengos et al. · Journal of Internal Medicine Open access	26 Jan 2004	388
29	Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial Fabrice André et al. · The Lancet Open access	20 Apr 2023	374
30	Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells Kalliopi I. Pappa, Alexander Polyzos, Jasmine Jacob‐Hirsch et al. · PLoS ONE Open access	11 Nov 2015	372
31	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) Antonio Pierangelo Palumbo et al. · Blood Open access	14 Aug 2011	357
32	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries Steen Dalby Kristensen et al. · European Heart Journal Open access114 authors	12 Jan 2014	352
33	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial Sebastian Grosicki et al. · The Lancet Open access	Nov 2020	339
34	Emerging treatment strategies for COVID-19 infection Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Eleni Korompoki et al. · Clinical and Experimental Medicine Open access	30 Oct 2020	339
35	Association Between Obesity and Mortality After Acute First-Ever Stroke Konstantinos N. Vemmos, George Ntaios, Konstantinos M. Spengos et al. · Stroke Open access	2 Dec 2010	335
36	In Vitro and In Vivo Inhibition of Helicobacter pylori by Lactobacillus casei Strain Shirota Dionyssios N. Sgouras, Petros A. Maragkoudakis, Kalliopi Petraki et al. · Applied and Environmental Microbiology Open access	2004	331
37	How I treat monoclonal gammopathy of renal significance (MGRS) Jean-Paul Fermand, Frank Bridoux, Robert A. Kyle et al. · Blood	10 Oct 2013	326
38	Obesity in Children and Adolescents during COVID-19 Pandemic Androniki Stavridou, Evangelia Kapsali, Eleni D. Panagouli et al. · Children Open access	12 Feb 2021	325
39	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 Silke Gillessen et al. · Annals of Oncology Open access	4 Jun 2015	324
40	Multiple myeloma Florent Malard, Paola E. Neri, Nizar Jacques Bahlis et al. · Nature Reviews Disease Primers Review	27 Jun 2024	321
41	Video‐laryngoscopes in the adult airway management: a topical review of the literature Panagiota Niforopoulou, Ioannis N. Pantazopoulos, Theano Demestiha et al. · Acta Anaesthesiologica Scandinavica	28 Jul 2010	320
42	Bisphosphonate-associated adverse events Peter D. Papapetrou · HORMONES Open access	Apr 2009	317
43	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer Christopher A. Haiman et al. · Nature Genetics Open access130 authors	30 Oct 2011	311
44	SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer Luis Chiva et al. · International Journal of Gynecological Cancer Open access147 authors	12 Aug 2020	307
45	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial Bradley J. Monk et al. · The Lancet Oncology	17 Jun 2014	307
46	Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation Konstantinos Stellos et al. · Nature Medicine Open access	5 Sep 2016	303
47	Platelet-derived chemokines in inflammation and atherosclerosis Constantinos Bakogiannis, Marco Sachse, Kimon S. Stamatelopoulos et al. · Cytokine	Dec 2017	295
48	Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke George Ntaios et al. · Stroke Open access	9 Jul 2020	287
49	Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting Frédéric Amant et al. · Annals of Oncology Open access	19 Aug 2019	287
50	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data Antonio Pierangelo Palumbo et al. · The Lancet Oncology Review	10 Feb 2014	287

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.